Office Action Predictor
Last updated: April 15, 2026
Application No. 18/472,895

FURANIC QUATERNARY AMMONIUM SALTS

Non-Final OA §112
Filed
Sep 22, 2023
Examiner
STOCKTON, LAURA LYNNE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Oregon State University
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1009 granted / 1342 resolved
+15.2% vs TC avg
Strong +34% interview lift
Without
With
+33.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
26 currently pending
Career history
1368
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
21.1%
-18.9% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
34.6%
-5.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1342 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-20 are pending in the instant application. Power of Attorney Of note, there is not an attorney of record on file due to a lack of an official power of attorney of record. While a customer number has been provided on the Application Data Sheet (ADS) submitted September 22, 2023, this is not the equivalent of a power of attorney or an authorization to act in a representative capacity. In order to expedite prosecution in the instant application, it is suggested that a power of attorney be filed as per MPEP §402 or MPEP §1807, or an Authorization to Act in a Representative Capacity be filed as per MPEP §403 in order for the Office to freely and openly discuss the merits of the case with the applicant's representative(s). Please refer to the MPEP or http://www.uspto.gov/patents/law/poafaqs.jsp#a if you have questions regarding the proper filing of a power of attorney. " Information Disclosure Statement The Examiner has considered the Information Disclosure Statement filed on September 22, 2023. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claim 16 is objected to because of the following informalities: “to” should be added after “reducing conditions” in the phrase “reducing conditions form a compound” (line 4 of the claim). Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 20 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 20 is unclear because claim 20 is incomplete. Claim 20 fails to clearly state the type of method (such as a method for treating). Further, claim 20 fails to state the purpose of the “administering” or state why the subject is in need of the compound. Therefore, claim 20 is indefinite. This rejection can be overcome by cancelling claim 20. Allowable Subject Matter Claims 1-15 and 17-19 are allowed over the prior art of record. The following is a statement of reasons for the indication of allowable subject matter. The instant claimed invention is directed to compounds of the formula, PNG media_image1.png 136 176 media_image1.png Greyscale , a pharmaceutical composition comprising a compound of the instant formula, and methods of making a compound of the instant formula. The novel and nonobvious aspect of this invention involves the definition of the instant R1 variable in the instant claimed compounds. The instant R1 substituent must have a minimum of 6 carbons in the optionally substituted alkyl. The closest prior art of record is Ponomarev et al. {Pharmaceutical Chemical Journal, 3(11), 621–625 (November 30, 1969)} who teach, for example, Compound XXV in Table 3 on page 624, PNG media_image2.png 174 1146 media_image2.png Greyscale PNG media_image3.png 226 996 media_image3.png Greyscale PNG media_image4.png 212 650 media_image4.png Greyscale PNG media_image5.png 72 956 media_image5.png Greyscale PNG media_image6.png 54 640 media_image6.png Greyscale . However, Ponomarev et al. fail to teach, suggest or motivate one skilled in the art toward the compounds of the instant claimed invention. See the definition of R1 in the compounds of Ponomarev et al. which corresponds to the position of the instant R1 variable in the instant claimed invention. Therefore, the instant claimed invention is free of the prior art of record. Reminder to Applicant As a reminder, Applicant should specifically point out the support in the original disclosure {i.e., page number(s) and line number(s)} for any new claims or amended claims and for any amendments made to the disclosure. Making generic statements such as “all amendments are fully supported in the originally filed disclosure or the originally filed claims” without specifying page numbers and originally filed claim numbers are insufficient. See MPEP §714.02 and MPEP §2163.06(I). Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Laura L. Stockton (571) 272-0710. The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor, James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620 Technology Center 1600 December 30, 2025 Book XXIX, page 35
Read full office action

Prosecution Timeline

Sep 22, 2023
Application Filed
Dec 01, 2025
Non-Final Rejection — §112
Mar 19, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590209
PIGMENTED AND FLUORESCENT COMPOUNDS DERIVED FROM THE ADDITION OF A PRIMARY OR SECONDARY AMINE TO AN ALDEHYDE
2y 5m to grant Granted Mar 31, 2026
Patent 12590060
SCALABLE SYNTHETIC ROUTE FOR PSILOCIN AND PSILOCYBIN
2y 5m to grant Granted Mar 31, 2026
Patent 12581853
ORGANIC COMPOUND AND SENSOR AND SENSOR EMBEDDED DISPLAY PANEL AND ELECTRONIC DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12577234
ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
2y 5m to grant Granted Mar 17, 2026
Patent 12566173
HEMOLYTIC REAGENT, REAGENT KIT, AND METHOD FOR CLASSIFYING WHITE BLOOD CELLS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+33.7%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1342 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month